Bremelanotide (PT-141)

HSDD is a common, treatable medical condition characterized by ongoing low sexual desire that patients find frustrating. If you’re diagnosed with “acquired, generalized” HSDD, it means you haven’t had low sexual desire in the past, but you now have low sexual desire no matter the sexual activity, situation, or sexual partner. It is a common condition occurring in > 10% of the female population and also can occur in men.

The FDA approved brand Vylessi is injectable bremelanotide indicated for HSDD in pre-menopausal women. The use of Bremelanotide, also known as PT 141, for other populations or in other combinations or forms such as oral troches or nasal sprays is considered off-label use and is not FDA regulated or approved. Medical providers may prescribe this peptide for purposes deemed appropriate and under medical supervision.

Darkening of the skin on certain parts of the body including the face, gums, and breasts can occur due to the stimulation of melanocytes in the brain. The chance of darkening of the skin is highest in people with darker skin color and for those who use it every day. Other common side effects are nausea, flushing, dizziness, and tingling which are usually transient lasting < 2 hours. Patients with uncontrolled high blood pressure or known coronary vascular disease should not use this peptide as it can cause a temporary rise in blood pressure

“Olympus” is an oral troche that contains a combination of two medications designed to enhance sexual arousal, increase sensitivity, boost energy, and intensify pleasure. This compounded formulation may also help address issues with low libido and reduce anxiety related to sexual performance. There is a formulation called Olympus Max that also includes Tadalafil, a popular medication for erectile dysfunction which also helps women in low dose with achievement of orgasm. If this is of potential use or interest to clients, you may message your doctor to discuss.